Mode
Text Size
Log in / Sign up
Phase 4 N=175 Randomized Treatment

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Hypertension in Pregnancy

Enrolled (actual)
175
Serious AEs
6.6%
Results posted
Oct 2024
Primary outcome: Primary: Length of Stay — 73.5; 72.0 hours

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Amlodipine (Drug); NIFEdipine ER (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Prisma Health-Upstate
Primary completion
Dec 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Length of Stay
73.5; 72.0
SECONDARY
Number of Acute Treatments After Medication Initiation
4.0; 1.5
SECONDARY
Patient Reported Side Effects
1.33; 1.60; 1.55; 1.71; 1.71; 1.98
SECONDARY
Number of Patients Discontinuing Medication Due to Side Effects
0; 7
SECONDARY
Number of Patients Requiring Hospital Readmission
3; 3
SECONDARY
Breastfeeding Duration of 6+ Weeks
4; 3
SECONDARY
Number of Patients Reporting Satisfaction With Breastfeeding Experience on Patient-completed Questionnaire
22; 32

Summary

A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol and nifedipine ER being the most commonly used medications. While these medications are both effective, they are not without limitations. Amlodipine is a medication in the same class as nifedipine ER. It is a first-line antihypertensive in the general population. It tends to have less side effects than nifedipine ER. It has not been studied specifically in postpartum women. The purpose of this study is to determine if amlodipine is noninferior to nifedipine ER in managing hypertension in the postpartum period.

Eligibility Criteria

Inclusion Criteria

  • Postpartum women with a diagnosis of chronic hypertension, gestational hypertension, or preeclampsia
  • Delivery at or beyond 20 weeks' gestation
  • Need for antihypertensive therapy, defined as blood pressure >/= 150 mmHg systolic and/or 100 mmHg diastolic on two occasions four hours apart or isolated blood pressure >160/110 mmHg
  • English or Spanish-speaking
  • Age 18 years or older

Exclusion Criteria

  • Use of antihypertensive prior to delivery (for any indication)
  • Allergy to nifedipine ER or amlodipine
  • Persistent tachycardia (as defined by the treatment team)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04790279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search